Drug-resistant tuberculosis: emerging treatment options

References

• World Health Organization2010/2011 Tuberculosis Global Facts [Internet]GenevaWorld Health Organization112010 Available from: http://www.who.int/tb/publications/2010/factsheet_tb_2010.pdfAccessed 4 Nov, 2011
   Google Scholar
• World Health OrganizationMultidrug and extensively drug resistant TB (M/XDR TB)Global Report on surveillance and response2010 Available from: http://www.who.int/tb/publications/2010/978924599191/en/index.htmlAccessed September 14, 2011
   Google Scholar
• Abu-RaddadLJSabatelliLAchterbergJTEpidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosticsProc Natl Acad Sci U S A2009106139801398519666590
   PubMed Web of Science ®Google Scholar
• MaZLienhardtCMcIlleronHNunnAJWangXGlobal tuberculosis drug development pipeline: the need and the realityLancet20103752100210920488518
   PubMed Web of Science ®Google Scholar
• GandhiNRNunnPDhedaKMultidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosisLancet20103751830184320488523
   PubMed Web of Science ®Google Scholar
• OrensteinEWBasuSShahNSTreatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisLancet Infect Dis2009915316119246019
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGlobal tuberculosis control – epidemiology, strategy, financing Global tuberculosis control: a short update to the 2009 reportGeneva, SwitzerlandWorld Health Organization2009
   Google Scholar
• VelayatiAAMasjediMRFarniaPEmergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in IranChest200913642042519349380
   PubMed Web of Science ®Google Scholar
• GinsbergAMEmerging drugs for active tuberculosisSemin Respir Crit Care Med20082955255918810688
   PubMed Web of Science ®Google Scholar
• LienhardtCVernonARaviglioneMCNew drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmesCurr Opin Pulm Med20101618619320216421
   PubMed Web of Science ®Google Scholar
• MitscherLABacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agentsChem Rev200510555959215700957
   PubMed Web of Science ®Google Scholar
• MoadebiSHarderCKFitzgeraldMJFluoroquinolones for the treatment of pulmonary tuberculosisDrugs2007672077209917883288
   PubMed Web of Science ®Google Scholar
• RodriguezJCRuizMClimentAIn vitro activity of four fluoroquinolones against Mycobacterium tuberculosisInt J Antimicrob Agents20011722923111282270
   PubMed Web of Science ®Google Scholar
• RustomjeeRLienhardtCKanyokTGatifloxacin for TB (OFLOTUB) Study TeamA Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosisInt J Tuberc Lung Dis20081212813818230244
   PubMed Web of Science ®Google Scholar
• NuermbergerELSpigelmanMKYewWWCurrent development and future prospects in chemotherapy of tuberculosisRespirology20101576477820546189
   PubMed Web of Science ®Google Scholar
• MehlhornAJBrownDASafety concerns with fluoroquinolonesAnn Pharmacother2007411859186617911203
   PubMed Web of Science ®Google Scholar
• BurmanWJGoldbergSJohnsonJLMoxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosisAm J Respir Crit Care Med200617433133816675781
   PubMed Web of Science ®Google Scholar
• CondeMBEfronALoredoCMoxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialLancet20093731183118919345831
   PubMed Web of Science ®Google Scholar
• DormanSEJohnsonJLGoldbergSTuberculosis Trials ConsortiumSubstitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisAm J Respir Crit Care Med200918027328019406981
   PubMed Web of Science ®Google Scholar
• MaZGinsburgAMSpigelmanMAntibacterial: antimycobacterial agentsTaylorJBTriggleDComprehensive Medicinal Chemistry IIOxford, UKElsevier2007
   Google Scholar
• DiekemaDJJonesRNOxazolidinone antibioticsLancet20013581975198211747939
   PubMed Web of Science ®Google Scholar
• ZurenkoGEYagiBHSchaadtRDIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsAntimicrob Agents Chemother1996408398458849237
   PubMed Web of Science ®Google Scholar
• WilliamsKNStoverCKZhuTPromising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine modelAntimicrob Agents Chemother2009531314131919075058
   PubMed Web of Science ®Google Scholar
• CondosRHadgiangelisNLeibertECase series report of a linezolid-containing regimen for extensively drug-resistant tuberculosisChest200813418719218628223
   PubMedGoogle Scholar
• AngerHADworkinFSharmaSLinezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000–06J Antimicrob Chemother20106577578320150181
   PubMed Web of Science ®Google Scholar
• NtzioraFFalagasMELinezolid for the treatment of patients with mycobacterial infections, a systematic reviewInt J Tuberc Lung Dis20071160661117519090
   PubMed Web of Science ®Google Scholar
• KohWJKwonOJGwakHDaily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosisJ Antimicrob Chemother20096438839119468028
   PubMed Web of Science ®Google Scholar
• WallisRSJakubiecWMKumarVPharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteersJ Infect Dis201020274575120629533
   PubMed Web of Science ®Google Scholar
• CynamonMHKlemensSPSharpeCAActivities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine modelAntimicrob Agents Chemother1999431189119110223934
   PubMed Web of Science ®Google Scholar
• WilliamsKNStoverCKZhuTPromising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine modelAntimicrob Agents Chemother2009531314131919075058
   PubMed Web of Science ®Google Scholar
• WilliamsKNBricknerSJStoverCKAddition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosisAm J Respir Crit Care Med200918037137619520903
   PubMed Web of Science ®Google Scholar
• GrossetJBacteriologic basis of short-course chemotherapy for tuberculosisClin Chest Med198012312416794976
   PubMed Web of Science ®Google Scholar
• MitchisonDARole of individual drugs in the chemotherapy of tuberculosisInt J Tuberc Lung Dis2000479680610985648
   PubMed Web of Science ®Google Scholar
• HeifetsLBLindholm-LevyPJFloryMABactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosisAm Rev Respir Dis19901416266302155555
   PubMed Web of Science ®Google Scholar
• KeungAEllerMGMcKenzieKASingle and multiple dose pharmacokinetics of rifapentine in man: Part IIInt J Tuberc Lung Dis1999343744410331734
   PubMed Web of Science ®Google Scholar
• LangdonGWilkinsJJSmithPJConsecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosisInt J Tuberc Lung Dis2004886286715260278
   PubMed Web of Science ®Google Scholar
• ZhangMAlmeidaDIsoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?Am J Respir Crit Care Med200817898999318723432
   PubMed Web of Science ®Google Scholar
• RosenthalIMWilliamsKTyagiSPotent twice-weekly rifapentine-containing regimens in murine tuberculosisAm J Respir Crit Care Med20061749410116574936
   PubMed Web of Science ®Google Scholar
• LenaertsAMChaseSEChmielewskiAJCynamonMHEvaluation of rifapentine in long-term treatment regimens for tuberculosis in miceAntimicrob Agents Chemother1999432356236010508006
   PubMed Web of Science ®Google Scholar
• GaoXFLiJYangZWLiYPRifapentine vs rifampicin for the treatment of pulmonary tuberculosis: a systematic reviewInt J Tuberc Lung Dis20091381081919555529
   PubMed Web of Science ®Google Scholar
• DiaconAHPymAGrobudchMThe diarylquinolone TMC207 for multi-drug-resistant tuberculosisN Engl J Med20093602397240519494215
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEuropean Medicines Agency Decision P/55252/2011 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500105081.pdfAccessed July 9, 2011
   Google Scholar
• SpigelmanMKCurrent and future therapeutic options for tuberculosisPresentation 2190 at the 45th American Society for Microbiology Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DCDecember 16–19, 2005
   Google Scholar
• AshtekarDRCosta-PeriraRNagrajanKIn vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosisAntimicrob Agents Chemother1993371831868452346
   PubMed Web of Science ®Google Scholar
• MatsumotoMHashizumeHTomishigeTOPC-67683, a nitro- dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in micePLoS Med2006321312144
   Web of Science ®Google Scholar
• StoverCKWarrenerPVanDevanterDRA small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature200040596296610879539
   PubMed Web of Science ®Google Scholar
• SinghRManjunathaUBoshoffHIPA-824 kills non-replicating Mycobacterium tuberculosis by intracellular NO releaseScience20083221392139519039139
   PubMed Web of Science ®Google Scholar
• ManjunathaUHBoshoffHDowdCSIdentification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosisProc Natl Acad Sci U S A200610343143616387854
   PubMed Web of Science ®Google Scholar
• LenaertsAJGruppoVMariettaKSPreclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo modelsAntimicrob Agents Chemother2005492294230115917524
   PubMed Web of Science ®Google Scholar
• HuYCoatesARMitchisonDAComparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosisInt J Tuberc Lung Dis200812697318173880
   PubMed Web of Science ®Google Scholar
• TyagiSNuermbergerEYoshimatsuTBactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosisAntimicrob Agents Chemother2005492289229315917523
   PubMed Web of Science ®Google Scholar
• NuermbergerERosenthalITyagiSCombination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosisAntimicrob Agents Chemother2006502621262516870750
   PubMed Web of Science ®Google Scholar
• TasneenRTyagiSWilliamsKEnhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosisAntimicrob Agents Chemother2008523664366818694943
   PubMed Web of Science ®Google Scholar
• NuermbergerETyagiSTasneenRPowerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosisAntimicrob Agents Chemother2008521522152418285479
   PubMed Web of Science ®Google Scholar
• GinsbergAMLaurenziMWRouseDJSafety, tolerability, and pharmacokinetics of PA-824 in healthy subjectsAntimicrob Agents Chemother2009533720372519528280
   PubMed Web of Science ®Google Scholar
• GinsbergADiaconADawsonRExtended early bactericidal activity (EBA) of PA-824, a novel drug for tuberculosis treatmentFinal Program of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual MeetingWashington, DCOctober 25–28, 2008
   Google Scholar
• [No authors listed]OPC-67683Tuberculosis (Edinb.)20088813213318486051
   PubMedGoogle Scholar
• DeiddaDLampisGFioravantiRBactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strainsAntimicrob Agents Chemother199842303530379797251
   PubMed Web of Science ®Google Scholar
• AroraSEradication of Mycobacterium tuberculosis infection in 2 months with LL-3858: a preclinical studyInt J Tuberc Lung Dis2004811 Suppl 1S29
   Web of Science ®Google Scholar
• Clinical Trials Registry, IndiaCTRI/2009/091/000741 Available at: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=922Accessed June 26, 2011
   Google Scholar
• ProtopopovaMHanrahanCNikonenkoBIdentification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediaminesJ Antimicrob Chemother20055696897416172107
   PubMed Web of Science ®Google Scholar
• ChenPGearhartJProtopopovaMSynergistic interactions of SQ109, a new ethylene diamine, with front-line anti-tubercular drugs in vitroJ Antimicrob Chemother20065833233716751637
   PubMed Web of Science ®Google Scholar
• Sequella Inc. SQ109 [Internet]Rockville, MDSequella Inc nd. Available at: http://www.sequella.com/docs/Sequella_1sheet_SQ109_TB_v3.pdfAccessed: Nov 4, 2011 Available at: http://www.sequella.com/docs/Sequella_1sheet_SQ109_TB_v3.pdfAccessed on June 25, 2011
   Google Scholar
• OnajoleOKBelewaXVCoovadiaYSQ109 analogues as potential antimicrobial candidatesMed Chem Res20112013941401
   Web of Science ®Google Scholar
• JiaLNokerPECowardLInterspecies pharmacokinetics and in vitro metabolism of SQ109Br J Pharmacol200614747648516432511
   PubMed Web of Science ®Google Scholar
• Sequella IncorporatedSQ609 therapeutic: preclinical indicationTreatment of pulmonary TB Available at: http://www.sequella.com/docs/Sequella_1sheet_SQ609_v1.pdfAccessed June 26, 2011
   Google Scholar
• Sequella IncorporatedSQ641 therapeutic: preclinical indicationBroad spectrum antibiotic Available at: http://www.sequella.com/docs/Sequella_1sheet_SQ641_v3.pdfAccessed on June 26, 2011
   Google Scholar
• ChuDTFernandesPBStructure-activity relationships in quinolone antibacterialsAntimicrob Agents Chemother1989331311352655528
   PubMed Web of Science ®Google Scholar
• ChuDTFernandesPBClaiborneAKStructure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolonesDrugs Exp Clin Res1988143793832850902
   PubMedGoogle Scholar
• WangQLucienEHashimotoAIsothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positionsJ Med Chem20075019921017228862
   PubMed Web of Science ®Google Scholar
• WilesJASongYWangQBiological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: in vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureusBioorg Med Chem Lett2006161277128116337789
   PubMed Web of Science ®Google Scholar
• PucciMJChengJPodosSDIn vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogensAntimicrob Agents Chemother2007511259126717242152
   PubMed Web of Science ®Google Scholar
• BrightyKEGootzTDChemistry and mechanism of action of the quinolone antibacterialsAndrioleVTThe Quinolones3rd edSan Diego, CAAcademic Press2000
   Google Scholar
• ChengJThanassiJAThomaCLDual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureusAntimicrob Agents Chemother2007512445245317502409
   PubMed Web of Science ®Google Scholar
• PucciMJAckermanMThanassiJAIn vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolonesusceptible and quinolone-resistant isolatesAntimicrob Agents Chemother2010543478348020516287
   PubMed Web of Science ®Google Scholar
• PucciMJPodosSDThanassiJAIn vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogensAntimicrob Agents Chemother2011552860287121464250
   PubMed Web of Science ®Google Scholar
• Stop TB PartnershipCPZEN-45 Available at: http://www.newtbdrugs.org/project.php?id=92Accessed June 26, 2011
   Google Scholar
• ChristopheTJacksonMJeonHKHigh content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitorsPLoS Pathog20095e100064519876393
   PubMed Web of Science ®Google Scholar
• MakarovVManinaGMikusovaKBenzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesisScience200932480181419299584
   PubMed Web of Science ®Google Scholar
• PascaMRDegiacomiGRibeiroALClinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinonesAntimicrob Agents Chemother2010541616161820086151
   PubMed Web of Science ®Google Scholar
• Quro ScienceQuro’s milestone for Quro Science Available at: http://www.quroscience.com/qurofile/pipe/pipe.htmlAccessed June 26, 2011
   Google Scholar
• Stop TB PartnershipQ201 novel anti-TB agent Available at: http://dev.newtbdrugs.org/project.php?id=176Accessed June 26, 2011
   Google Scholar
• ReddyVMO’SullivanJFGangadharamPRAntimycobacterial activities of riminophenazinesJ Antimicrob Chemother1999361562310382882
   PubMed Web of Science ®Google Scholar
• TB AllianceChina pioneers R&D Center Available at: http://www.tballiance.org/new/portfolio/html-portfolio-item.php?id=14Accessed June 26, 2011
   Google Scholar
• Stop TB StrategyBuilding on and enhancing DOTS to meet the TB-related millennium development goals Available at: http://www.ghdonline.org/drtb/resource/the-stop-tb-strategy-building-on-and-enhancing-dot/Accessed September 14, 2011
   Google Scholar
• RowlandRMcShaneHTuberculosis vaccines in clinical trialsExpert Rev Vaccines201110564565821604985
   PubMed Web of Science ®Google Scholar
• KaufmanSHEHusseyGLambertPNew vaccines for tuberculosisLancet20103752110211920488515
   PubMed Web of Science ®Google Scholar
• RussellDGBarryCEFlynnJLTuberculosis: What we don’t know can, and does, hurt usScience201032885285620466922
   PubMed Web of Science ®Google Scholar
• Von EschenKMorrisonRBraunMThe candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humansHum Vaccin2009547548219587528
   PubMed Web of Science ®Google Scholar
• WingfieldCThe Tuberculosis Vaccine PipelineTAG Pipeline Report2010Sec-2140148
   Google Scholar
• BeresfordBSadoffJCUpdate on research and development pipeline: Tuberculosis vaccinesClin Inf Dis201050 Suppl 3S178S183
   Web of Science ®Google Scholar
• Stop TB PartnershipTuberculosis vaccine candidates2009 Available at: http://www.stoptb.org/wg/new_vaccines/assets/documents/TB%20Vaccine%20Pipeline%2009%20final.pdfAccessed September 14, 2011
   Google Scholar
• HarringtonMCreating political will and scientific momentum to develop a point-of-care test for TBPresented at the Fourteenth TB/HIV Core Group Meeting of the Stop TB PartnershipAddis Ababa, EthiopiaNovember 12, 2008
   Google Scholar
• SyedJThe Tuberculosis Diagnostic PipelineTAG Pipeline Report2010Sec-2107124
   Google Scholar
• Check-HaydenEMarket overlap points to irresponsible use of tuberculosis drugsNat Med20111763521647122
   PubMed Web of Science ®Google Scholar
• PalominoJCRamosDFDa SilvaPANew anti-tuberculosis drugs: strategies, sources and new moleculesCurr Med Chem2009161898190419442153
   PubMed Web of Science ®Google Scholar
• KinningsSLLiuNBuchmeierNDrug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosisPLoS Comput Biol20095e100042319578428
   PubMed Web of Science ®Google Scholar
• DuttaNKMehraSKaushalDA Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazinePLoS One20105e1006920386700
   PubMed Web of Science ®Google Scholar
• DuttaNKMazumdarKDastidarSGNew patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspectiveRecent Pat Antiinfect Drug Discov2011612813821517741
   PubMedGoogle Scholar
• AmaralLBoereeMJGillespieSHThioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!Int J Antimicrob Agents20103552452620188526
   PubMed Web of Science ®Google Scholar
• ZhengFXieJThe interaction topology of Mycobacterium tuberculosis genes responsive to capreomycin and novel clues for more drug targetsJ Cell BiochemJune 1520111122716272021678479
   PubMed Web of Science ®Google Scholar
• EohHBrennanPJCrickDCThe Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug targetTuberculosis (Edinb)20098911118793870
   PubMed Web of Science ®Google Scholar
• RajniMeenaLSGuanosine triphosphatases as novel therapeutic targets in tuberculosisInt J Infect Dis201014e682e68720207570
   PubMed Web of Science ®Google Scholar
• Torres-RomeroDJiménezIARojasRDihydro-β-agarofuran sesquiterpenes isolated from Celastrus vulcanicola as potential anti-Mycobacterium tuberculosis multidrug-resistant agentsBioorg Med Chem2011192182218921419633
   PubMed Web of Science ®Google Scholar
• León-DíazRMeckesMSaid-FernándezSAntimycobacterial neolignans isolated from Aristolochia taliscanaMem Inst Oswaldo Cruz2010105455120209328
   PubMed Web of Science ®Google Scholar
• ZanettiSCannasSMolicottiPEvaluation of the antimicrobial properties of the essential oil of Myrtus communis L. against clinical strains of Mycobacterium sppInterdiscip Perspect Infect Dis7292010 [Epub ahead of print.]
   Google Scholar
• GuptaRThakurBSinghPAnti-tuberculosis activity of selected medicinal plants against multi-drug resistant Mycobacterium tuberculosis isolatesIndian J Med Res201013180981320571171
   PubMed Web of Science ®Google Scholar
• AdhvaryuMRVakhariaBCIntegrating herbal formulation with conventional ATT improves prognosis in complicated TB in addition to preventing hepatotoxicityAbstract presented at the Shanghai International Tuberculosis ConferenceShanghai, ChinaMarch 18–20, 2011
   Google Scholar
• ParkSKKimJHKangHPulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosisInt J Infect Dis20091317017518768342
   PubMed Web of Science ®Google Scholar
• DravnieceGCainKPHoltzTHAdjunctive resectional lung surgery for extensively drug-resistant tuberculosisEur Respir J20093418018319567603
   PubMed Web of Science ®Google Scholar
• YaldizSGursoySUcvetASurgery offers high cure rates in multidrug-resistant tuberculosisAnn Thorac Cardiovasc Surg20111714314721597410
   PubMed Web of Science ®Google Scholar
• PandeyRKhullerGKAntitubercular inhaled therapy: opportunities, progress and challengesJ Antimicrob Chemother20055543043515761077
   PubMed Web of Science ®Google Scholar
• Garcia-ContrerasLSungJCMuttilPDry powder PA-824 aerosols for treatment of tuberculosis in guinea pigsAntimicrob Agents Chemother2010541436144220086154
   PubMed Web of Science ®Google Scholar
• ZumlaAWallisRDohertyMJoint TDR/EC expert consultation on biomarkers in tuberculosis: report of the joint TDR/EC expert consultation to evaluate the potential roles of biomarkers in the management of HIV-infected and HIV-uninfected patients with tuberculosisGeneva, SwitzerlandJuly 2–3, 2008 Available at: http:apps.who.int/tdr/publications/tdr-research-publications/biomarkers/pdf/biomarkers.pdfAccessed Sep 15, 2011
   Google Scholar
• SpigelmanMWoosleyRGheuensJNew initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decadesInt J Tuberc Lung Dis20101466366420487601
   PubMed Web of Science ®Google Scholar